80308-80-1Relevant academic research and scientific papers
Structure-Guided Discovery of Aminoquinazolines as Brain-Penetrant and Selective LRRK2 Inhibitors
Acton, John J.,Adpressa, Donovon,Ardolino, Michael J.,Bennett, David Jonathan,Chau, Ryan W.,Ciaccio, Paul J.,Dimauro, Erin F.,Faltus, Robert,Fell, Matthew J.,Fuller, Peter H.,Gulati, Anmol,Hegde, Laxminarayan G.,Johnson, Rebecca E.,Kattar, Solomon D.,Kennedy, Matthew E.,Keylor, Mitchell H.,Lesburg, Charles A.,Lin, Shishi,Liu, Ping,Margrey, Kaila A.,McMinn, Spencer E.,Morriello, Gregori J.,Neelamkavil, Santhosh,Nogle, Lisa,Otte, Karin M.,Palte, Rachel L.,Piesvaux, Jennifer,Pio, Barbara,Poremba, Kelsey E.,Simov, Vladimir,Su, Jing,Wood, Harold B.,Woodhouse, Janice D.,Xiong, Tina,Yan, Xin,Zarate, Cayetana
, p. 838 - 856 (2022/01/20)
The leucine-rich repeat kinase 2 (LRRK2) protein has been genetically and functionally linked to Parkinson's disease (PD), a disabling and progressive neurodegenerative disorder whose current therapies are limited in scope and efficacy. In this report, we
N-(HETEROARYL) QUINAZOLIN-2-AMINE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
-
Page/Page column 68-69, (2021/04/30)
The present invention is directed to substituted certain N-(heteroaryl)quinazolin-2-amine derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein J, R3, and R4, are as defined herein, which are potent inhib
The N-vinyl group as a protection group of the preparation of 3(5)-substituted pyrazoles via bromine-lithium exchange
Iddon, Brian,T?nder, Janne Ejrn?s,Hosseini, Masood,Begtrup, Mikael
, p. 56 - 61 (2007/10/03)
Treatment of 3,4,5-tribromopyrazole with 1,2-dibromoethane and triethylamine gave 3,4,5-tribromo-1-vinylpyrazole, which underwent regioselective bromine-lithium exchange at the 5-position. Subsequent addition of an electrophile gave 5-substituted 3,4-dibr
